Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) (vol 5, e368, 2015)

被引：12
|
作者：
Phillips, D. C.
Xiao, Y.
Lam, L. T.
Litvinovich, E.
Roberts-Rapp, L.
Souers, A. J.
Leverson, J. D.
机构：
来源：
BLOOD CANCER JOURNAL | 2016年 / 6卷
关键词：
D O I：
10.1038/bcj.2016.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Correction to: Blood Cancer Journal (2015) 5, e368; doi:10.1038/bcj.2015.88; published online 13 November 2015 Following the publication of this article, the authors noted the following errors: 1. The final sentence in the legend of Figure 1 should be 'Data are presented as the mean±s.e.m. of one-two experiments each in triplicate'.
引用
收藏
页码：e403 / e403
页数：1
相关论文
共 18 条
  • [1] Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    D C Phillips
    Y Xiao
    L T Lam
    E Litvinovich
    L Roberts-Rapp
    A J Souers
    J D Leverson
    Blood Cancer Journal, 2015, 5 : e368 - e368
  • [2] Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    Phillips, D. C.
    Xiao, Y.
    Lam, L. T.
    Litvinovich, E.
    Roberts-Rapp, L.
    Souers, A. J.
    Leverson, J. D.
    BLOOD CANCER JOURNAL, 2015, 5 : e368 - e368
  • [3] Erratum: Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    D C Phillips
    Y Xiao
    L T Lam
    E Litvinovich
    L Roberts-Rapp
    A J Souers
    J D Leverson
    Blood Cancer Journal, 2016, 6 : e403 - e403
  • [4] A potent and selective small molecule inhibitor of MCL-1 sensitizes DLBCL cell lines to the BCL-2 selective inhibitor ABT-199
    Phillips, D. C.
    Xiao, Y.
    Lam, L.
    Litinovic, E.
    Roberts-Rapp, L.
    Souers, A. J.
    Leverson, J. D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 130 - 130
  • [5] Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
    Luedtke, Daniel A.
    Niu, Xiaojia
    Pan, Yihang
    Zhao, Jianyun
    Liu, Shuang
    Edwards, Holly
    Chen, Kang
    Lin, Hai
    Taub, Jeffrey W.
    Ge, Yubin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2017, 2
  • [6] Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
    Daniel A Luedtke
    Xiaojia Niu
    Yihang Pan
    Jianyun Zhao
    Shuang Liu
    Holly Edwards
    Kang Chen
    Hai Lin
    Jeffrey W Taub
    Yubin Ge
    Signal Transduction and Targeted Therapy, 2
  • [7] The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    de Vos, Sven
    Flowers, Christopher R.
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan
    Reid, Erin
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Yang, Jianning
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod A.
    Kozloff, Mark
    BLOOD, 2014, 124 (21)
  • [8] Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia
    Luedtke, Daniel A.
    Su, Yongwei
    Edwards, Holly
    Lin, Hai
    Taub, Jeffrey W.
    Ge, Yubin
    BLOOD, 2017, 130
  • [9] High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
    Bate-Eya, Laurel T.
    den Hartog, Ilona J. M.
    van der Ploeg, Ida
    Schild, Linda
    Koster, Jan
    Santo, Evan E.
    Westerhout, Ellen M.
    Versteeg, Rogier
    Caron, Huib N.
    Molenaar, Jan J.
    Dolman, M. Emmy M.
    ONCOTARGET, 2016, 7 (19) : 27946 - 27958
  • [10] The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients
    Davids, Matthew S.
    Seymour, John F.
    Gerecitano, John F.
    Kahl, Brad S.
    Pagel, John M.
    Wierda, William G.
    Anderson, Mary-Ann
    Rudersdorf, Nikita K.
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Jianning
    Busman, Todd A.
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    BLOOD, 2013, 122 (21)
12